Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Penault-Llorca

Showing results (61-70 of 141) with videos related to

Pageof 15
Sort By:
Annales De Pathologie|September 1, 1996
[Pancreatic and duodenal somatostatinoma. Two clinico-pathologic entities]M P Mathoulin-Portier, M J Payan, G Monges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classesF-C Bidard, M-C Matthieu, P Chollet, et al.
Annales De Pathologie|April 4, 1998
[Clear cell sarcoma of the kidney relapsing after 10 years of asymptomatic evolution]E Charafe, F Penault-Llorca, M P Mathoulin-Portier, et al.
Anticancer Research|August 5, 2010
Zinc-alpha2-glycoprotein: a new biomarker of breast cancer?V Dubois, L Delort, F Mishellany, et al.
The International Journal of Biological Markers|May 23, 2006
Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancerP J Lamy, I Nanni, F Fina, et al.
British Journal of Cancer|May 29, 2003
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancerL Arnould, Y Denoux, G MacGrogan, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|November 21, 2000
[Assessment of different histoprognosis grading systems for primary ovarian cancer: 100 patients given the same treatment for primary ovarian adenocarcinoma]F Penault-Llorca, O Levrel, A Clémenson, et al.
Cancer Genetics and Cytogenetics|February 24, 2001
New cytogenetic data on bladder carcinoma cell line (CHA89) revealed by M-FISH analysisB Perissel, M Giollant, N Dastugue, et al.
Oncology Research|March 25, 2006
Does survival increase in metastatic breast cancer with recently available anticancer drugs?C Abrial, M Leheurteur, A Cabrespine, et al.
Medical Oncology (Northwood, London, England)|August 20, 2005
Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancersC Abrial, M A Mouret-Reynier, S Amat, et al.
Pageof 15

Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Annales De Pathologie|September 1, 1996
[Pancreatic and duodenal somatostatinoma. Two clinico-pathologic entities]M P Mathoulin-Portier, M J Payan, G Monges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classesF-C Bidard, M-C Matthieu, P Chollet, et al.
Annales De Pathologie|April 4, 1998
[Clear cell sarcoma of the kidney relapsing after 10 years of asymptomatic evolution]E Charafe, F Penault-Llorca, M P Mathoulin-Portier, et al.
Anticancer Research|August 5, 2010
Zinc-alpha2-glycoprotein: a new biomarker of breast cancer?V Dubois, L Delort, F Mishellany, et al.
The International Journal of Biological Markers|May 23, 2006
Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancerP J Lamy, I Nanni, F Fina, et al.
British Journal of Cancer|May 29, 2003
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancerL Arnould, Y Denoux, G MacGrogan, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|November 21, 2000
[Assessment of different histoprognosis grading systems for primary ovarian cancer: 100 patients given the same treatment for primary ovarian adenocarcinoma]F Penault-Llorca, O Levrel, A Clémenson, et al.
Cancer Genetics and Cytogenetics|February 24, 2001
New cytogenetic data on bladder carcinoma cell line (CHA89) revealed by M-FISH analysisB Perissel, M Giollant, N Dastugue, et al.
Oncology Research|March 25, 2006
Does survival increase in metastatic breast cancer with recently available anticancer drugs?C Abrial, M Leheurteur, A Cabrespine, et al.
Medical Oncology (Northwood, London, England)|August 20, 2005
Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancersC Abrial, M A Mouret-Reynier, S Amat, et al.
Pageof 15